AgNovos Healthcare is developing new treatments for osteoporosis, a devastating bone disease affecting more than 200 million women worldwide.
With osteoporosis, the normal bone remodeling process is unbalanced. This imbalance leads to lower bone mass and poorer bone quality, causing a reduction in bone strength and increased risk of fracture. When patients suffer a fracture, many experience a cascade of consequences that includes loss of mobility and independence, depression and increased mortality.1
AgNovos' pioneering approach to treating patients with osteoporosis is based on experience from our founder's career in clinical practice.
The Company has conducted extensive pre-clinical and clinical research on its first treatment, OSSURETM LOEP® (Local Osteo-Enhancement Procedure). This research shows that OSSURE LOEP can immediately, substantially and durably increase the density and strength of treated bones.2
1 Kanis JA (2007) WHO Technical Report, University of Sheffield UK: 66
2 Howe et al., World Congress on Osteoporosis 2017; Hill et al., ECTS 2017; Keaveny et al., ASBMR 2017
AgNovos is a high-energy, employee-centric company comprised of experienced colleagues who share a deep commitment to the company mission of helping individuals maintain their mobility, independence, and quality of life.
Careers at AgNovos
We are often seeking qualified candidates. Applicants are encouraged to visit our Careers section or LinkedIn page for more information. If you do not see a job description that matches your skills and experience, please submit your cover letter and resume so that we can keep your information on file with the appropriate department. Click here to email your cover letter and resume details.
The AgNovos Way
AgNovos is committed to act in a way that is consistent with our core values and our personal commitment to helping individuals and physicians confronting bone disease. We will continually reach for new discoveries, technologies, and programs that improve bone health and education so that we can help families, communities, and the world move forward with more confidence.
AgNovos Research Interests
AgNovos recognizes that we must work with our partners in healthcare to change the world for millions of individuals who suffer from bone disease. AgNovos’ first treatment targets individuals with osteoporosis. We are always interested in better understanding the science that underpins bone disease and our treatment.
The name AgNovos is derived from a combination of two Latin words that translate roughly as: to recognize, to understand, and to innovate.
Dr. James Howe founded AgNovos Healthcare after a 34-year career as an orthopedic surgeon during which he witnessed the personal, societal, and economic costs of
bone diseases such